Wall Street brokerages forecast that Johnson & Johnson (NYSE:JNJ) will announce $19.91 billion in sales for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Johnson & Johnson’s earnings, with the lowest sales estimate coming in at $19.71 billion and the highest estimate coming in at $20.17 billion. Johnson & Johnson posted sales of $19.65 billion during the same quarter last year, which indicates a positive year-over-year growth rate of 1.3%. The company is scheduled to issue its next quarterly earnings report on Tuesday, October 16th.
On average, analysts expect that Johnson & Johnson will report full year sales of $81.11 billion for the current year, with estimates ranging from $80.89 billion to $81.32 billion. For the next year, analysts forecast that the business will post sales of $83.91 billion per share, with estimates ranging from $81.84 billion to $86.26 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Johnson & Johnson.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 17th. The company reported $2.10 EPS for the quarter, beating the Zacks’ consensus estimate of $2.06 by $0.04. The company had revenue of $20.83 billion during the quarter, compared to analysts’ expectations of $20.39 billion. Johnson & Johnson had a return on equity of 32.79% and a net margin of 1.70%. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter last year, the business posted $1.83 EPS.
A number of research analysts recently weighed in on the company. ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. Sanford C. Bernstein assumed coverage on Johnson & Johnson in a research report on Wednesday, June 27th. They set a “market perform” rating and a $129.00 price objective for the company. Jefferies Financial Group set a $145.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research report on Sunday, July 15th. Credit Suisse Group set a $151.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research report on Tuesday, June 12th. Finally, Goldman Sachs Group raised Johnson & Johnson from a “sell” rating to a “neutral” rating in a research report on Thursday, July 12th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the company. Johnson & Johnson has an average rating of “Hold” and an average price target of $142.87.
In other Johnson & Johnson news, COO Michael E. Sneed sold 29,000 shares of Johnson & Johnson stock in a transaction on Monday, August 27th. The stock was sold at an average price of $134.80, for a total value of $3,909,200.00. Following the completion of the sale, the chief operating officer now owns 59,124 shares of the company’s stock, valued at approximately $7,969,915.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Ronald A. Kapusta sold 7,899 shares of Johnson & Johnson stock in a transaction on Friday, September 7th. The stock was sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the sale, the chief accounting officer now directly owns 25,725 shares of the company’s stock, valued at approximately $3,528,955.50. The disclosure for this sale can be found here. 0.22% of the stock is currently owned by company insiders.
Institutional investors have recently bought and sold shares of the business. Financial Gravity Wealth Inc. bought a new stake in shares of Johnson & Johnson in the first quarter worth $105,000. CSat Investment Advisory L.P. bought a new stake in shares of Johnson & Johnson in the second quarter worth $107,000. Stelac Advisory Services LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter worth $108,000. WP Advisors LLC bought a new stake in shares of Johnson & Johnson in the second quarter worth $108,000. Finally, FNY Investment Advisers LLC bought a new stake in shares of Johnson & Johnson in the second quarter worth $117,000. 66.80% of the stock is owned by institutional investors and hedge funds.
JNJ stock opened at $139.49 on Friday. Johnson & Johnson has a twelve month low of $118.62 and a twelve month high of $148.32. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.65 and a quick ratio of 1.33. The company has a market cap of $373.89 billion, a P/E ratio of 17.87, a P/E/G ratio of 2.13 and a beta of 0.69.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 11th. Shareholders of record on Tuesday, August 28th were issued a $0.90 dividend. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.58%. The ex-dividend date of this dividend was Monday, August 27th. Johnson & Johnson’s payout ratio is 49.32%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: Penny Stocks, Risk and Reward Factors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.